Base de dados : MEDLINE
Pesquisa : E02.095.410 [Categoria DeCS]
Referências encontradas : 3784 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 379 ir para página                         

  1 / 3784 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173974
[Au] Autor:Pugnet G; Castilla-Llorente C; Puyade M; Terriou L; Badoglio M; Deligny C; Guillaume-Jugnot P; Labeyrie C; Benzidia I; Faivre H; Lansiaux P; Marjanovic Z; Bourhis JH; Faucher C; Furst S; Huynh A; Martin T; Vermersch P; Yakoub-Agha I; Farge D
[Ad] Endereço:CHU de Toulouse, hôpital Purpan, service de médecine interne, 1, place Baylac, 31059 Toulouse, France.
[Ti] Título:[Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
[Ti] Título:Indications et suivi des autogreffes de cellules souches hématopoïétiques dans les maladies auto-immunes et auto-inflammatoires : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)..
[So] Source:Bull Cancer;104(12S):S169-S180, 2017 Dec.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 7th allogeneic hematopoietic stem cell transplantation clinical practices harmonization workshop series in September 2017 in Lille, France and updated recommendations for indications and follow-up in autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases, previously published under the auspices of SFGM-TC.
[Mh] Termos MeSH primário: Doenças Autoimunes/terapia
Doença de Crohn/terapia
Escleroderma Sistêmico/terapia
[Mh] Termos MeSH secundário: Autoenxertos
Doenças Autoimunes do Sistema Nervoso/terapia
Seguimentos
França
Mobilização de Células-Tronco Hematopoéticas/normas
Transplante de Células-Tronco Hematopoéticas/efeitos adversos
Transplante de Células-Tronco Hematopoéticas/normas
Seres Humanos
Imunossupressores/efeitos adversos
Lúpus Eritematoso Sistêmico/terapia
Sociedades Médicas
Condicionamento Pré-Transplante/normas
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Nm] Nome de substância:
0 (Immunosuppressive Agents)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171228
[Lr] Data última revisão:
171228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  2 / 3784 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775695
[Au] Autor:Ben Abdejlil N; Belloumi D; Mâammar M; El Fatimi R; Torjman L; Lakhal A; Jenhani F; Hmida S; Ben Othman T; Ladeb S
[Ad] Endereço:Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.
[Ti] Título:Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country.
[So] Source:Bone Marrow Transplant;52(2):222-227, 2017 Feb.
[Is] ISSN:1476-5365
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study compared retrospectively the effectiveness, toxicity and hematopoietic recovery after autologous peripheral blood stem cell transplantation (ASCT) of two consecutive peripheral blood stem cell mobilization regimens in newly diagnosed MM patients. Patients in group 1 (n=178) were treated with 4 g/m of cyclophosphamide (CY) plus G-CSF (5 µg/kg/day). Patients in group 2 (n=117) with 750 mg/m of VP16 plus G-CSF (10 µg/kg/day). Optimal mobilization, defined by a target number of 8 × 10 CD34+ cells/kg collected, was achieved in 62.4% and 89.7% of patients in groups 1 and 2, respectively (P<10 ). The median number of aphaeresis sessions was reduced from two in group 1 to one in group 2 (P<10 ). Grade neutropenia, febrile neutropenia and IV antibiotic use were significantly more frequent in group 1 than in group 2 (P<10 ). Red blood cell transfusion requirements were significantly greater in group 1 (P=0.007). The switch to VP16-G-CSF resulted in a significant reduction of the number of hospitalization days (P<10 ). Neutrophil and platelet recovery after ASCT occurred on days 11 and 12, respectively, in the two groups with no significant differences. VP +G-CSF allowed liberation of resources in the clinical and aphaeresis departments and demonstrated a better effectiveness-safety profile than CY+G-CSF .
[Mh] Termos MeSH primário: Ciclofosfamida/administração & dosagem
Fator Estimulador de Colônias de Granulócitos/administração & dosagem
Mobilização de Células-Tronco Hematopoéticas/métodos
Mieloma Múltiplo/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Aloenxertos
Feminino
Seres Humanos
Masculino
Meia-Idade
Transplante de Células-Tronco de Sangue Periférico
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
143011-72-7 (Granulocyte Colony-Stimulating Factor); 8N3DW7272P (Cyclophosphamide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1038/bmt.2016.246


  3 / 3784 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28895846
[Au] Autor:Richter M; Stone D; Miao C; Humbert O; Kiem HP; Papayannopoulou T; Lieber A
[Ad] Endereço:Division of Medical Genetics, University of Washington, 1705 NE Pacific Street, Seattle, WA 98195, USA.
[Ti] Título:In Vivo Hematopoietic Stem Cell Transduction.
[So] Source:Hematol Oncol Clin North Am;31(5):771-785, 2017 Oct.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Current protocols for hematopoietic stem cell (HSC) gene therapy, involving the transplantation of ex vivo lentivirus vector-transduced HSCs into myeloablated recipients, are complex and not without risk for the patient. In vivo HSC gene therapy can be achieved by the direct modification of HSCs in the bone marrow after intraosseous injection of gene delivery vectors. A recently developed approach involves the mobilization of HSCs from the bone marrow into peripheral the blood circulation, intravenous vector injection, and re-engraftment of genetically modified HSCs in the bone marrow. We provide examples for in vivo HSC gene therapy and discuss advantages and disadvantages.
[Mh] Termos MeSH primário: Terapia Genética
Vetores Genéticos/genética
Células-Tronco Hematopoéticas/metabolismo
Transdução Genética
[Mh] Termos MeSH secundário: Animais
Células da Medula Óssea/citologia
Células da Medula Óssea/metabolismo
Edição de Genes
Expressão Gênica
Técnicas de Transferência de Genes
Terapia Genética/métodos
Vetores Genéticos/administração & dosagem
Vetores Genéticos/classificação
Mobilização de Células-Tronco Hematopoéticas/métodos
Células-Tronco Hematopoéticas/citologia
Seres Humanos
Transgenes
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170913
[St] Status:MEDLINE


  4 / 3784 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28879595
[Au] Autor:Partanen A; Valtola J; Ropponen A; Vasala K; Penttilä K; Ågren L; Pyörälä M; Nousiainen T; Selander T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
[Ad] Endereço:Department of Medicine, Kuopio University Hospital, P.O.B. 100, 70029 KYS, Kuopio, Finland. anu.partanen@kuh.fi.
[Ti] Título:Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.
[So] Source:Ann Hematol;96(11):1897-1906, 2017 Nov.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Filgrastim is usually combined with chemotherapy to mobilize hematopoietic progenitor cells in non-Hodgkin lymphoma (NHL) patients. Limited information is available on the efficacy of a preemptive plerixafor (PLER) injection in poor mobilizers after chemotherapy and pegfilgrastim. In this prospective study, 72 patients with NHL received chemotherapy plus pegfilgrastim, and 25 hard-to-mobilize patients received also PLER. The usefulness and efficacy of our previously developed algorithm for PLER use in pegfilgrastim-containing mobilization regimen were evaluated as well as the graft cellular composition, hematological recovery, and outcome after autologous stem cell transplantation (auto-SCT) according to the PLER use. A median 3.4-fold increase in blood CD34 cell counts was achieved after the first PLER dose. The minimum collection target was achieved in the first mobilization attempt in 66/72 patients (92%) and 68 patients (94%) proceeded to auto-SCT. An algorithm for PLER use was fulfilled in 76% of the poor mobilizers. Absolute numbers of T-lymphocytes and NK cells were significantly higher in the PLER group, whereas the number of CD34 cells collected was significantly lower. Early neutrophil engraftment was slower in the PLER group, otherwise hematological recovery was comparable within 12 months from auto-SCT. No difference was observed in survival according to the PLER use. Chemotherapy plus pegfilgrastim combined with preemptive PLER injection is an effective and convenient approach to minimize collection failures in NHL patients intended for auto-SCT. A significant effect of PLER on the graft cellular composition was observed, but no difference in outcome after auto-SCT was detected.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Fator Estimulador de Colônias de Granulócitos/administração & dosagem
Mobilização de Células-Tronco Hematopoéticas/tendências
Compostos Heterocíclicos/administração & dosagem
Linfoma não Hodgkin/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Carmustina/administração & dosagem
Citarabina/administração & dosagem
Quimioterapia Combinada
Feminino
Filgrastim
Mobilização de Células-Tronco Hematopoéticas/métodos
Seres Humanos
Injeções Subcutâneas
Linfoma não Hodgkin/sangue
Linfoma não Hodgkin/diagnóstico
Masculino
Melfalan/administração & dosagem
Meia-Idade
Podofilotoxina/administração & dosagem
Polietilenoglicóis
Estudos Prospectivos
Proteínas Recombinantes/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Heterocyclic Compounds); 0 (Recombinant Proteins); 04079A1RDZ (Cytarabine); 143011-72-7 (Granulocyte Colony-Stimulating Factor); 155148-31-5 (JM 3100); 30IQX730WE (Polyethylene Glycols); 3A58010674 (pegfilgrastim); L36H50F353 (Podophyllotoxin); PVI5M0M1GW (Filgrastim); Q41OR9510P (Melphalan); U68WG3173Y (Carmustine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170908
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3123-6


  5 / 3784 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28801449
[Au] Autor:Río P; Navarro S; Guenechea G; Sánchez-Domínguez R; Lamana ML; Yañez R; Casado JA; Mehta PA; Pujol MR; Surrallés J; Charrier S; Galy A; Segovia JC; Díaz de Heredia C; Sevilla J; Bueren JA
[Ad] Endereço:Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.
[Ti] Título:Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34 cells from Fanconi anemia patients.
[So] Source:Blood;130(13):1535-1542, 2017 Sep 28.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Previous Fanconi anemia (FA) gene therapy studies have failed to demonstrate engraftment of gene-corrected hematopoietic stem and progenitor cells (HSPCs) from FA patients, either after autologous transplantation or infusion into immunodeficient mice. In this study, we demonstrate that a validated short transduction protocol of G-CSF plus plerixafor-mobilized CD34 cells from FA-A patients with a therapeutic lentiviral vector corrects the phenotype of in vitro cultured hematopoietic progenitor cells. Transplantation of transduced FA CD34 cells into immunodeficient mice resulted in reproducible engraftment of myeloid, lymphoid, and CD34 cells. Importantly, a marked increase in the proportion of phenotypically corrected, patient-derived hematopoietic cells was observed after transplantation with respect to the infused CD34 graft, indicating the proliferative advantage of corrected FA-A hematopoietic repopulating cells. Our data demonstrate for the first time that optimized protocols of hematopoietic stem cell collection from FA patients, followed by the short and clinically validated transduction of these cells with a therapeutic lentiviral vector, results in the generation of phenotypically corrected HSPCs capable of repopulating and developing proliferation advantage in immunodeficient mice. Our results suggest that clinical approaches for FA gene therapy similar to those used in this study will facilitate hematopoietic repopulation in FA patients with gene corrected HSPCs, opening new prospects for gene therapy of FA patients.
[Mh] Termos MeSH primário: Proteína do Grupo de Complementação C da Anemia de Fanconi/genética
Anemia de Fanconi/terapia
Terapia Genética/métodos
Vetores Genéticos
Transplante de Células-Tronco Hematopoéticas/métodos
Transdução Genética/métodos
[Mh] Termos MeSH secundário: Animais
Antígenos CD34/imunologia
Criança
Pré-Escolar
Anemia de Fanconi/patologia
Sobrevivência de Enxerto
Mobilização de Células-Tronco Hematopoéticas
Células-Tronco Hematopoéticas/patologia
Xenoenxertos
Seres Humanos
Lentivirus/genética
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD34); 0 (Fanconi Anemia Complementation Group C Protein)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170813
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2017-03-774174


  6 / 3784 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28783041
[Au] Autor:Oguro H; McDonald JG; Zhao Z; Umetani M; Shaul PW; Morrison SJ
[Ad] Endereço:Children's Research Institute and.
[Ti] Título:27-Hydroxycholesterol induces hematopoietic stem cell mobilization and extramedullary hematopoiesis during pregnancy.
[So] Source:J Clin Invest;127(9):3392-3401, 2017 Sep 01.
[Is] ISSN:1558-8238
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Extramedullary hematopoiesis (EMH) is induced during pregnancy to support rapid expansion of maternal blood volume. EMH activation requires hematopoietic stem cell (HSC) proliferation and mobilization, processes that depend upon estrogen receptor α (ERα) in HSCs. Here we show that treating mice with estradiol to model estradiol increases during pregnancy induced HSC proliferation in the bone marrow but not HSC mobilization. Treatment with the alternative ERα ligand 27-hydroxycholesterol (27HC) induced ERα-dependent HSC mobilization and EMH but not HSC division in the bone marrow. During pregnancy, 27HC levels increased in hematopoietic stem/progenitor cells as a result of CYP27A1, a cholesterol hydroxylase. Cyp27a1-deficient mice had significantly reduced 27HC levels, HSC mobilization, and EMH during pregnancy but normal bone marrow hematopoiesis and EMH in response to bleeding or G-CSF treatment. Distinct hematopoietic stresses thus induce EMH through different mechanisms. Two different ERα ligands, estradiol and 27HC, work together to promote EMH during pregnancy, revealing a collaboration of hormonal and metabolic mechanisms as well as a physiological function for 27HC in normal mice.
[Mh] Termos MeSH primário: Hematopoese Extramedular/efeitos dos fármacos
Mobilização de Células-Tronco Hematopoéticas/métodos
Hidroxicolesteróis/farmacologia
[Mh] Termos MeSH secundário: Animais
Células da Medula Óssea/citologia
Proliferação Celular
Colestanotriol 26-Mono-Oxigenase/genética
Estradiol/metabolismo
Receptor alfa de Estrogênio/metabolismo
Feminino
Citometria de Fluxo
Células-Tronco Hematopoéticas/fisiologia
Ligantes
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Gravidez
Prenhez
Células-Tronco/citologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Estrogen Receptor alpha); 0 (Hydroxycholesterols); 0 (Ligands); 4TI98Z838E (Estradiol); 6T2NA6P5SQ (27-hydroxycholesterol); EC 1.14.15.15 (Cholestanetriol 26-Monooxygenase); EC 1.14.15.15 (Cyp27a1 protein, mouse)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170808
[St] Status:MEDLINE


  7 / 3784 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28681435
[Au] Autor:Partanen A; Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Putkonen M; Sankelo M; Pelkonen J; Mäntymaa P; Varmavuo V; Jantunen E
[Ad] Endereço:Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
[Ti] Título:Impact of lenalidomide-based induction therapy on the mobilization of CD34 cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.
[So] Source:Transfusion;57(10):2366-2372, 2017 Oct.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Lenalidomide is an immunomodulatory drug that is also currently used in transplant-eligible patients with multiple myeloma. Previous studies have suggested a negative impact of lenalidomide on the mobilization of CD34 cells. No data are available regarding the more detailed composition of blood grafts after lenalidomide. STUDY DESIGN AND METHODS: In a multicenter, prospective study, we analyzed the mobilization of CD34 cells, graft cellular composition, and post-transplant hematologic recovery in 26 patients with multiple myeloma after lenalidomide-based induction and in 34 lenalidomide-naive controls with multiple myeloma. All patients were mobilized with low-dose cyclophosphamide plus granulocyte-colony-stimulating factor. The cellular composition of the grafts was analyzed from thawed, cryopreserved samples with flow cytometry. Graft function was evaluated by engraftment data and by complete blood counts until 12 months after the graft infusion. RESULTS: Patients in the lenalidomide arm had lower median peak CD34 counts and approximately 40% lower CD34 cell yields from the first apheresis session, but these differences were not significant. The median total number of CD34 cells collected was comparable (6.4 vs. 7.5 × 10 /kg). The number of apheresis sessions was higher in the lenalidomide group (2 vs. 1; p = 0.039). The blood graft composition was comparable between the groups. Hematologic recovery within 12 months post-transplant did not differ between the groups. CONCLUSION: Lenalidomide-based induction seems to have an impact on the number of aphereses performed, but not on the total yields of the CD34 cells in the graft. Neither cellular composition of the grafts nor post-transplant recovery was affected by the limited pre-transplant exposure to lenalidomide.
[Mh] Termos MeSH primário: Mobilização de Células-Tronco Hematopoéticas/métodos
Quimioterapia de Indução
Mieloma Múltiplo/terapia
Talidomida/análogos & derivados
[Mh] Termos MeSH secundário: Idoso
Antígenos CD34/análise
Antígenos CD34/efeitos dos fármacos
Estudos de Casos e Controles
Feminino
Sobrevivência de Enxerto/efeitos dos fármacos
Células-Tronco Hematopoéticas/citologia
Células-Tronco Hematopoéticas/efeitos dos fármacos
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Talidomida/farmacologia
Talidomida/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antigens, CD34); 4Z8R6ORS6L (Thalidomide); F0P408N6V4 (lenalidomide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14220


  8 / 3784 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28675459
[Au] Autor:Shastri A; Budhathoki A; Barta SK; Kornblum N; Derman O; Battini R; Raghupathy R; Verma AK; Frenette PS; Braunschweig I; Janakiram M
[Ad] Endereço:Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York.
[Ti] Título:Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.
[So] Source:Am J Hematol;92(10):1047-1051, 2017 Oct.
[Is] ISSN:1096-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hematopoietic stem cell (HSC) release is positively regulated by the sympathetic nervous system through the ß3 adrenergic receptor. Preclinical studies have demonstrated that the combination of desipramine and G-CSF resulted in improved HSC mobilization. Here, we present the results of an open-label single-arm pilot study in patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) to assess the safety and efficacy of desipramine combined with G-SCF to induce HSC mobilization. The primary endpoint was safety of the combination including engraftment kinetics. The secondary endpoint was the proportion of patients who collected ≥5 × 10 CD34 cells/kg. Outcomes were compared with historical matched controls during the same time period with multiple myeloma mobilized with G-CSF. All study patients received desipramine 100 mg daily for 7 days, starting 4 days prior to G-CSF administration (D-3) and continued taking it along with G-CSF for a total of 7 days. Six of ten patients enrolled completed the protocol with minimal side effects. All of them achieved the target collection of 5 × 10 CD34 cells/kg in a median of 1.5 apheresis session with two patients needing additional plerixafor (16%), while 11 out of 13 patients (85%) achieved the target of 5 × 10 CD34 cells/kg in the historical control group in a median of 2 apheresis procedures and seven patients needed plerixafor (54%). The combination of desipramine and G-CSF is safe and signals improved mobilization over G-CSF alone, providing a possible alternative means of mobilization that needs further investigation.
[Mh] Termos MeSH primário: Inibidores da Captação Adrenérgica/uso terapêutico
Antígenos CD34/imunologia
Desipramina/uso terapêutico
Fator Estimulador de Colônias de Granulócitos/uso terapêutico
Mobilização de Células-Tronco Hematopoéticas/métodos
Transplante de Células-Tronco Hematopoéticas
Mieloma Múltiplo/terapia
[Mh] Termos MeSH secundário: Adolescente
Inibidores da Captação Adrenérgica/administração & dosagem
Adulto
Idoso
Desipramina/administração & dosagem
Quimioterapia Combinada
Feminino
Fator Estimulador de Colônias de Granulócitos/administração & dosagem
Fator Estimulador de Colônias de Granulócitos/efeitos adversos
Células-Tronco Hematopoéticas/efeitos dos fármacos
Células-Tronco Hematopoéticas/imunologia
Células-Tronco Hematopoéticas/metabolismo
Compostos Heterocíclicos/administração & dosagem
Compostos Heterocíclicos/efeitos adversos
Compostos Heterocíclicos/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Mieloma Múltiplo/sangue
Projetos Piloto
Receptores Adrenérgicos beta 3/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic Uptake Inhibitors); 0 (Antigens, CD34); 0 (Heterocyclic Compounds); 0 (Receptors, Adrenergic, beta-3); 143011-72-7 (Granulocyte Colony-Stimulating Factor); 155148-31-5 (JM 3100); TG537D343B (Desipramine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1002/ajh.24843


  9 / 3784 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28666004
[Au] Autor:Shin S; Kim J; Kim-Wanner SZ; Bönig H; Cho SR; Kim S; Choi JR; Lee KA
[Ad] Endereço:Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:A novel association between relaxin receptor polymorphism and hematopoietic stem cell yield after mobilization.
[So] Source:PLoS One;12(6):e0179986, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood is a complex mechanism that involves adhesive and chemotactic interactions of HSCs as well as their bone marrow microenvironment. In addition to a number of non-genetic factors, genetic susceptibilities also contribute to the mobilization outcome. Identification of genetic factors associated with HSC yield is important to better understand the mechanism behind HSC mobilization. In the present study, we enrolled 148 Korean participants (56 healthy donors and 92 patients) undergoing HSC mobilization for allogeneic or autologous HSC transplantation. Among a total of 53 polymorphisms in 33 candidate genes, one polymorphism (rs11264422) in relaxin/insulin-like family peptide receptor 4 (RXFP4) gene was significantly associated with a higher HSC yield after mobilization in Koreans. However, in a set of 101 Europeans, no association was found between circulating CD34+ cell counts and rs11264422 genotype. Therefore, we suggest that the ethnic differences in subjects' genetic background may be related to HSC mobilization. In conclusion, the relaxin-relaxin receptor axis may play an important role in HSC mobilization. We believe that the results of the current study could provide new insights for therapies that use relaxin and HSC populations, as well as a better understanding of HSC regulation and mobilization at the molecular level.
[Mh] Termos MeSH primário: Mobilização de Células-Tronco Hematopoéticas
Transplante de Células-Tronco Hematopoéticas
Polimorfismo de Nucleotídeo Único
Receptores Acoplados a Proteínas-G/genética
Receptores de Peptídeos/genética
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, G-Protein-Coupled); 0 (Receptors, Peptide); 0 (relaxin receptors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170701
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179986


  10 / 3784 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28653421
[Au] Autor:Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
[Ad] Endereço:Department of Medicine V, Heidelberg University, Heidelberg, Germany.
[Ti] Título:Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
[So] Source:Transfusion;57(10):2359-2365, 2017 Oct.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Granulocyte-colony-stimulating factor (G-CSF) originators such as filgrastim (Neupogen) and lenograstim (Granocyte) are widely used for peripheral blood stem cell (PBSC) mobilization. In recent years, biosimilar agents have been approved for the same indications. The aim of this retrospective study was to compare the mobilization efficiency of the three G-CSF variants originator filgrastim, lenograstim, and the biosimilar Filgrastim Hexal in a homogeneous group of multiple myeloma (MM) patients in first-line therapy. STUDY DESIGN AND METHODS: Overall mobilization data of 250 patients with MM were included. Of these patients, 74 (30%), 131 (52%), and 45 (18%) were mobilized with originator filgrastim, biosimilar Filgrastim Hexal, or lenograstim, respectively, at a dose of 5 to 10 µg/kg body weight subcutaneously starting from Day 5 after chemomobilization with CAD (cyclophosphamide, doxorubicin, dexamethasone) until completion of PBSC collection. RESULTS: All but one patient reached the collection goal of a minimum of at least 2 × 10 CD34+ cells/kg body weight during a median of one (range, one to three) leukapheresis session. No significant differences in CD34+ mobilization and collection yields between the filgrastim-mobilized (median, 10.5; range, 2.7-40.4), Filgrastim Hexal-mobilized (median, 9.9; range, 0.2-26.0), and lenograstim-mobilized (median, 10.7; range, 3.1-27.9 CD34+ cells × 10 /kg body weight) patients were observed. CONCLUSION: Concerning the clinically relevant efficiencies of PBSC mobilization and in terms of reaching the individual collection target, this retrospective study did not detect any significant differences between the three G-CSF variants in the analyzed patient cohort.
[Mh] Termos MeSH primário: Medicamentos Biossimilares/normas
Mobilização de Células-Tronco Hematopoéticas/métodos
Mieloma Múltiplo/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Antígenos CD34/análise
Medicamentos Biossimilares/uso terapêutico
Feminino
Filgrastim/normas
Filgrastim/uso terapêutico
Fator Estimulador de Colônias de Granulócitos/normas
Fator Estimulador de Colônias de Granulócitos/uso terapêutico
Mobilização de Células-Tronco Hematopoéticas/normas
Seres Humanos
Leucaférese
Masculino
Meia-Idade
Proteínas Recombinantes/normas
Proteínas Recombinantes/uso terapêutico
Estudos Retrospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD34); 0 (Biosimilar Pharmaceuticals); 0 (Recombinant Proteins); 143011-72-7 (Granulocyte Colony-Stimulating Factor); 6WS4C399GB (lenograstim); PVI5M0M1GW (Filgrastim)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14211



página 1 de 379 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde